drugset / Trial / NCT06430671
Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis
Phase 1
Completed
11 enrolled
Cellerys AG
Jung Diagnostics GmbH · collabNovartis · collabScope International AG · collabTetec AG · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
RED4MS is a clinical trial to assess the safety and tolerability of autologous peptide coupled red blood cells (CLS12311) in patients with relapsing remitting multiple sclerosis (RRMS). CLS12311 consists of autologous red blood cells (RBCs) coupled with antigenic peptides and aims to treat RRMS by induction of antigen-specific immune tolerance.
Timeline
- Start
- 2024-06-18
- Primary completion
- 2025-12-23
- Completion
- 2025-12-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CLS12311 | Unknown | — | — |